PATENT CLAIM ANALYSIS

Application Number: 16451040
Application Type: Utility
Filing Date: 2019-06
Publication Date: 2019-10
Patent Classification: ["424", "190100"]

Abstract:
The present invention is directed to methods of preventing reactivation of active and latent  M. tuberculosis  infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a  M. tuberculosis  infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a  M. tuberculosis  infection.

Claim (Index 16):
The method of  claim 12 , wherein the host cell is a mammalian cell.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 100.0
- Lexical Diversity: 1.61404
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13895574', '16135553', '15463557', '14603935', '10369983']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7425551201042198
- 35 USC 102 Novelty (BERT): 0.5398030852945979
- Combined Prediction Score: 0.7222799166232576
- Mean Citation Score: 336.32422000000014
- Max Citation Score: 361.7533
- Similarity Product: 232.2600507687688

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test